metaEvidence - overview


			deaths (OS)	progression or deaths (PFS)	RFS/DFS
mML - NA - all population metastatic/adv melanoma (mML) mML - (neo)adjuvant (NA) mML - NA - all population
versus interferon alpha
	Ipilimumab (10 mg/kg) vs. interferon alpha	1	0.88 [0.69; 1.12], 1 RCT, I2=0% inconclusive result	-	0.84 [0.65; 1.09], 1 RCT, I2=0% inconclusive result
versus placebo
	Ipilimumab (10 mg/kg) vs. placebo	1	0.72 [0.58; 0.89], 1 RCT, I2=0% conclusive unassessable degree of certainty	-	0.75 [0.63; 0.89], 1 RCT, I2=0% conclusive unassessable degree of certainty
mML - NA - PDL1 positive metastatic/adv melanoma (mML) mML - (neo)adjuvant (NA) mML - NA - PDL1 positive
mML - L1 - all population metastatic/adv melanoma (mML) mML - 1st line (L1) mML - L1 - all population
mML - L1 - BRAF mutant metastatic/adv melanoma (mML) mML - 1st line (L1) mML - L1 - BRAF mutant
mML - L1 - BRAF wild metastatic/adv melanoma (mML) mML - 1st line (L1) mML - L1 - BRAF wild
mML - L2 - all population metastatic/adv melanoma (mML) mML - 2nd line (L2) mML - L2 - all population
versus ipilimumab alone
	Ipilimumab (10 mg/kg) vs. ipilimumab alone	1	0.84 [0.71; 1.00], 1 RCT, I2=0% conclusive unassessable degree of certainty	0.89 [0.66; 1.21], 1 RCT, I2=0% inconclusive result	-
mML - L2 - BRAF mutant metastatic/adv melanoma (mML) mML - 2nd line (L2) mML - L2 - BRAF mutant